Kunihito Goto
Papers
1
Total Citations
13
H-Index
1
About
Kunihito Goto is a clinical researcher whose work centers on the safety and real-world application of novel therapies for advanced gastric cancer (AGC). His major contributions focus on identifying and characterizing rare but critical adverse events associated with emerging targeted treatments, particularly for HER2-negative, CLDN18.2-positive disease. Goto’s most cited paper, a 2025 case report in a high-impact journal, documents the first detailed descriptions of protein-losing enteropathy induced by zolbetuximab in patients with unresectable AGC. This work, which has already garnered 13 citations, provides essential safety data that complements the landmark GLOW and SPOTLIGHT trials, helping clinicians anticipate and manage this serious complication in real-world practice. By bridging the gap between clinical trial efficacy and everyday patient care, Goto’s research directly informs treatment decision-making and improves outcomes for a difficult-to-treat population. His findings underscore the importance of vigilant post-marketing surveillance for novel biologics, establishing him as a key voice in the evolving landscape of gastric cancer therapeutics.
Research Focus
Key Achievements
Top Papers
- 1